Literature DB >> 23304419

Improving the accuracy of therapy descriptions in clinical trials using a bottom-up approach.

Maurine Tong1, Ricky K Taira.   

Abstract

Randomized clinical trial (RCT) reports commonly have complicated therapy descriptions that are written in free-text. Drug therapy is difficult to describe due to the dynamic nature of how protocols change and the many ways drugs can be administered. Details regarding protocol changes and drug administration must be explained clearly for reproducibility and reliability. A process model supplemented with concept ontologies can clarify the dynamics of how therapies change and make knowledge more explicit. We demonstrated the process to develop a representation model to reveal specific context concerning drug therapies within clinical trial report literature. A PubMed search was conducted to identify RCTs on non-small-cell lung cancer (NSCLC) pertaining to epithelial growth factor receptor (EGFR) mutations. Twenty-seven clinical trials were used to develop the model using a bottom-up approach. This representation describes drug dosage, administration details, and drug cycles within different experimental arms and control groups. We then presented preliminary evaluation of the clarity and understandability of the representation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23304419      PMCID: PMC3540541     

Source DB:  PubMed          Journal:  AMIA Annu Symp Proc        ISSN: 1559-4076


  14 in total

1.  Electronic trial banks: a complementary method for reporting randomized trials.

Authors:  I Sim; D K Owens; P W Lavori; G D Rennels
Journal:  Med Decis Making       Date:  2000 Oct-Dec       Impact factor: 2.583

2.  The Trial Bank system: capturing randomized trials for evidence-based medicine.

Authors:  Ida Sim; Ben Olasov; Simona Carini
Journal:  AMIA Annu Symp Proc       Date:  2003

3.  CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials.

Authors:  David Moher; Sally Hopewell; Kenneth F Schulz; Victor Montori; Peter C Gøtzsche; P J Devereaux; Diana Elbourne; Matthias Egger; Douglas G Altman
Journal:  BMJ       Date:  2010-03-23

4.  Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer.

Authors:  Katharine A Price; Christopher G Azzoli; Lee M Krug; Maria C Pietanza; Naiyer A Rizvi; William Pao; Mark G Kris; Gregory J Riely; Robert T Heelan; Maria E Arcila; Vincent A Miller
Journal:  J Thorac Oncol       Date:  2010-10       Impact factor: 15.609

5.  Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors.

Authors:  Timothy A Yap; Laura Vidal; Jan Adam; Peter Stephens; James Spicer; Heather Shaw; Jooern Ang; Graham Temple; Susan Bell; Mehdi Shahidi; Martina Uttenreuther-Fischer; Peter Stopfer; Andrew Futreal; Hilary Calvert; Johann S de Bono; Ruth Plummer
Journal:  J Clin Oncol       Date:  2010-08-02       Impact factor: 44.544

Review 6.  Epidermal growth factor receptor mutations in lung cancer.

Authors:  Sreenath V Sharma; Daphne W Bell; Jeffrey Settleman; Daniel A Haber
Journal:  Nat Rev Cancer       Date:  2007-03       Impact factor: 60.716

7.  Standardizing clinical trials workflow representation in UML for international site comparison.

Authors:  Elias Cesar Araujo de Carvalho; Madhav Kishore Jayanti; Adelia Portero Batilana; Andreia M O Kozan; Maria J Rodrigues; Jatin Shah; Marco R Loures; Sunita Patil; Philip Payne; Ricardo Pietrobon
Journal:  PLoS One       Date:  2010-11-09       Impact factor: 3.240

8.  Modeling biomedical experimental processes with OBI.

Authors:  Ryan R Brinkman; Mélanie Courtot; Dirk Derom; Jennifer M Fostel; Yongqun He; Phillip Lord; James Malone; Helen Parkinson; Bjoern Peters; Philippe Rocca-Serra; Alan Ruttenberg; Susanna-Assunta Sansone; Larisa N Soldatova; Christian J Stoeckert; Jessica A Turner; Jie Zheng
Journal:  J Biomed Semantics       Date:  2010-06-22

9.  Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.

Authors:  David H Johnson; Louis Fehrenbacher; William F Novotny; Roy S Herbst; John J Nemunaitis; David M Jablons; Corey J Langer; Russell F DeVore; Jacques Gaudreault; Lisa A Damico; Eric Holmgren; Fairooz Kabbinavar
Journal:  J Clin Oncol       Date:  2004-06-01       Impact factor: 44.544

10.  Frequency and reasons for outcome reporting bias in clinical trials: interviews with trialists.

Authors:  R M D Smyth; J J Kirkham; A Jacoby; D G Altman; C Gamble; P R Williamson
Journal:  BMJ       Date:  2011-01-06
View more
  1 in total

1.  Evaluating a Novel Summary Visualization for Clinical Trial Reports: A Usability Study.

Authors:  Maurine Tong; William Hsu; Ricky K Taira
Journal:  AMIA Annu Symp Proc       Date:  2017-02-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.